VakilNvan ZantenSVKahrilasPDentJJonesR, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900-1920;quiz 1943. doi:10.1111/j.1572-0241.2006.00630.x
2.
DentJVakilNJonesR, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut. 2010;59(6):714-721. doi:10.1136/gut.2009.200063
3.
KahrilasPJBoeckxstaensGSmoutAJPM. Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27(3):401-414. doi:10.1016/j.bpg.2013.06.005
4.
SigtermanKEvan PinxterenBBonisPALauJNumansME.Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095. doi:10.1002/14651858.CD002095.pub5
5.
BytzerPJonesRVakilN, et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10(12):1360-1366. doi:10.1016/j.cgh.2012.06.030
6.
GyawaliCPCarlsonDAChenJWPatelAWongRJYadlapatiRH.ACG clinical guidelines: clinical use of esophageal physiologic testing. Am J Gastroenterol. 2020;115(9):1412-1428. doi:10.14309/ajg.0000000000000734
7.
ZerbibFBredenoordAJFassR, et al. ESNM/ANMS consensus paper: diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil. 2021;33(4):e14075. doi:10.1111/nmo.14075
8.
JacobsonBCSomersSCFuchsCSKellyCPCamargoCA.Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354(22):2340-2348. doi:10.1056/NEJMoa054391
El-SeragH.The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci. 2008;53(9):2307-2312. doi:10.1007/s10620-008-0413-9
11.
SternEKCarlsonDAFalmagneS, et al. Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients. Neurogastroenterol Motil. 2018;30(2). doi:10.1111/nmo.13247
Ness-JensenELindamALagergrenJHveemK.Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol. 2013;108(3):376-382. doi:10.1038/ajg.2012.466
GrahamDYTanselA.Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;16(6):800-808.e7. doi:10.1016/j.cgh.2017.09.033
16.
InadomiJ.Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003;98(9):1940-1944. doi:10.1016/S0002-9270(03)00628-2
17.
GyawaliCPKahrilasPJSavarinoE, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67(7):1351-1362. doi:10.1136/gutjnl-2017-314722
18.
PohCHGasiorowskaANavarro-RodriguezT, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc. 2010;71(1):28-34. doi:10.1016/j.gie.2009.08.024
19.
XieCLiYZhangNXiongLChenMXiaoY.Gastroesophageal flap valve reflected EGJ morphology and correlated to acid reflux. BMC Gastroenterol. 2017;17(1):118. doi:10.1186/s12876-017-0693-7
20.
HansdotterIBjörOAndreassonA, et al. Hill classification is superior to the axial length of a hiatal hernia for assessment of the mechanical anti-reflux barrier at the gastroesophageal junction. Endosc Int Open. 2016;4(3):E311-E317. doi:10.1055/s-0042-101021
21.
ScarpullaGCamilleriSGalantePManganaroMFoxM.The impact of prolonged pH measurements on the diagnosis of gastroesophageal reflux disease: 4-day wireless pH studies. Am J Gastroenterol. 2007;102(12):2642-2647. doi:10.1111/j.1572-0241.2007.01461.x
22.
PrakashCClouseRE.Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2005;3(4):329-334. doi:10.1016/s1542-3565(05)00021-2
23.
PatelRKumarAChaeSJacobsJRichterJ.96 Hour esophageal ph monitoring the tiebreaker for abnormal demeester score and symptom index. J Gastrointest Disord. Published online August 20, 2019. doi:10.1016/S0016-5085(18)31852-3
24.
YadlapatiRMasihiMGyawaliCP, et al. Ambulatory reflux monitoring guides proton pump inhibitor discontinuation in patients with gastroesophageal reflux symptoms: a clinical trial. Gastroenterology. 2021;160(1):174-182.e1. doi:10.1053/j.gastro.2020.09.013
25.
HasakSYadlapatiRAltayarO, et al. Prolonged wireless ph monitoring in patients with persistent reflux symptoms despite proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2020;18(13):2912-2919. doi:10.1016/j.cgh.2020.01.031
26.
YadlapatiRCiolinoJDCraftJRomanSPandolfinoJE.Trajectory assessment is useful when day-to-day esophageal acid exposure varies in prolonged wireless pH monitoring. Dis Esophagus. 2019;32(3):doy077. doi:10.1093/dote/doy077
27.
DesjardinMLucGColletDZerbibF.24-Hour pH-impedance monitoring on therapy to select patients with refractory reflux symptoms for antireflux surgery. A single center retrospective study. Neurogastroenterol Motil. 2016;28(1):146-152. doi:10.1111/nmo.12715
28.
RomanSGyawaliCPSavarinoE, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil. 2017;29(10):1-15. doi:10.1111/nmo.13067
29.
KahrilasPJBoeckxstaensG.Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients?Gut. 2012;61(10):1501-1509. doi:10.1136/gutjnl-2011-301898
30.
ChibaNDe GaraCJWilkinsonJMHuntRH.Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798-1810. doi:10.1053/gast.1997.v112.pm9178669
31.
FacklerWKOursTMVaeziMFRichterJE.Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122(3):625-632. doi:10.1053/gast.2002.31876
32.
AshidaKSakuraiYHoriT, et al. Randomised clinical trial: vonoprazan a novel potassium-competitive acid blocker vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240-251. doi:10.1111/apt.13461
33.
KoekGHSifrimDLerutTJanssensJTackJ.Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003;52(10):1397-1402. doi:10.1136/gut.52.10.1397
34.
LeimanDARiffBPMorganS, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30(5):1-9. doi:10.1093/dote/dow020
35.
ManabeNHarumaKItoM, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus. 2012;25(5):373-380. doi:10.1111/j.1442-2050.2011.01276.x
36.
Dominguez-ProfetaRCheverieJNBlitzerRR, et al. More beads, more peristaltic reserve, better outcomes: factors predicting postoperative dysphagia after magnetic sphincter augmentation. Surg Endosc. Published online October 30, 2020. doi:10.1007/s00464-020-08013-5
37.
PattiMGRobinsonTGalvaniCGorodnerMVFisichellaPMWayLW.Total fundoplication is superior to partial fundoplication even when esophageal peristalsis is weak. J Am Coll Surg. 2004;198(6):863-869;discussion 869. doi:10.1016/j.jamcollsurg.2004.01.029
38.
StoikesNDrapekinJKushnirVShakerABruntLMGyawaliCP.The value of multiple rapid swallows during preoperative esophageal manometry before laparoscopic antireflux surgery. Surg Endosc. 2012;26(12):3401-3407. doi:10.1007/s00464-012-2350-0
39.
BoothMIStratfordJJonesLDehnTCB. Randomized clinical trial of laparoscopic total (Nissen) versus posterior partial (Toupet) fundoplication for gastro-oesophageal reflux disease based on preoperative oesophageal manometry. Br J Surg. 2008;95(1):57-63. doi:10.1002/bjs.6047
40.
FrezzaEEIkramuddinSGourashW, et al. Symptomatic improvement in gastroesophageal reflux disease (GERD) following laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2002;16(7):1027-1031. doi:10.1007/s00464-001-8313-5
41.
SavarinoEZentilinPTutuianR, et al. Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. J Gastroenterol. 2012;47(2):159-168. doi:10.1007/s00535-011-0480-0
42.
RiehlMEKeeferL.Hypnotherapy for esophageal disorders. Am J Clin Hypn. 2015;58(1):22-33. doi:10.1080/00029157.2015.1025355
43.
LiXDingFLuoP, et al. Study on the therapeutic effects of drug and cognitive-behavioral therapy on non-erosive reflux disease patients with emotional disorders. Front Psychiatry. 2018;9:115. doi:10.3389/fpsyt.2018.00115
44.
RiehlMEKinsingerSKahrilasPJPandolfinoJEKeeferL.Role of a health psychologist in the management of functional esophageal complaints. Dis Esophagus. 2015;28(5):428-436. doi:10.1111/dote.12219
45.
YamasakiTFassR.Reflux hypersensitivity: a new functional esophageal disorder. J Neurogastroenterol Motil. 2017;23(4):495-503. doi:10.5056/jnm17097
